Michael Schneiders becomes new CFO
Michael Schneiders took over as Chief Financial Officer (CFO) of BRAIN Biotech AG on October 1, 2022. He succeeds Lukas Linnig, who will be responsible for the Akribion Genomics activities together with BRAIN Biotech´s longtime R&D Head Dr. Michael Krohn in the future.
Michael Schneiders has more than twenty years of experience in the capital market – with a strong focus on German equities and international institutional investors. Prior to joining BRAIN, the economist held various management positions in investment banking, including Head of Equities & Research.
Schneiders was already involved in BRAIN's IPO in 2016. In May 2020, he had joined the company as Head of Investor Relations and Sustainability.